학술논문
Simplifying Type 2 DM Care with Linagliptin: A Position Paper.
Document Type
Academic Journal
Author
Mithal A; Chairman and Head, Department of Endocrinology and Diabetes, Max Healthcare, Delhi.; Ramachandran A; Chairman, Dr A Ramachandran's Diabetes Hospitals; President, India Diabetes Research Foundation (IDRF), Chennai, Tamil Nadu; Corresponding Author.; Bhattacharyya A; Consultant Endocrinologist, Manipal Hospital, Bengaluru, Karnataka.; Chadha M; Senior Consultant Endocrinologist, Hinduja Hospital, Mumbai, Maharashtra.; Dharmalingam M; Director and Head, Department of Endocrinology, Bangalore Endocrinology and Diabetes Research Centre, Bengaluru, Karnataka.; Majumder A; Professor, Department of Endocrinology, KPC Medical College.; Sanyal D; Professor, Department of Endocrinology, KPC Medical College, Kolkata, India; Conjoint Professor, University of Newcastle, Callaghan Australia.
Source
Publisher: Association of Physicians of India Country of Publication: India NLM ID: 7505585 Publication Model: Print Cited Medium: Print ISSN: 0004-5772 (Print) Linking ISSN: 00045772 NLM ISO Abbreviation: J Assoc Physicians India Subsets: MEDLINE
Subject
Language
English
ISSN
0004-5772
Abstract
Introduction: The burden of type 2 diabetes mellitus (T2DM) is raising dramatically both internationally and in India. It is often observed that multiple therapies or combinations of different drugs are usually required to successfully control hyperglycemia in patients with T2DM. To facilitate effective control of glucose levels, many new agents have been developed over the past few years.
Materials and Methods: Multiple Advisory Board Meetings were conducted with 87 leading key opinion leaders (KOLs) from diabetes specialty PAN India to understand the simplicity aspect of linagliptin therapy in T2DM patients.
Discussion: Linagliptin is a xanthine-based, non-peptidomimetic, selective dipeptidyl peptidase 4 (DPP-4) inhibitor with a different pharmacological profile when compared to other DPP-4 inhibitors already available in India. It is known to decrease the risk of hypoglycemia compared to sulphonylurea (SU), is weight neutral, and no dose modification is required over a broad range of patient populations. This consensus paper discusses the clinical efficacy of DPP-4 inhibitors and linagliptin in T2DM. It also highlights the evidence for the safety of linagliptin in T2DM patients with renal impairment (RI), cardiovascular (CV) risk, and heart failure (HF).
Conclusion: Linagliptin therapy is simplifying the management of T2DM with good efficacy and its use across a wide range of patients without any dose modification.
(© Journal of the Association of Physicians of India 2011.)
Materials and Methods: Multiple Advisory Board Meetings were conducted with 87 leading key opinion leaders (KOLs) from diabetes specialty PAN India to understand the simplicity aspect of linagliptin therapy in T2DM patients.
Discussion: Linagliptin is a xanthine-based, non-peptidomimetic, selective dipeptidyl peptidase 4 (DPP-4) inhibitor with a different pharmacological profile when compared to other DPP-4 inhibitors already available in India. It is known to decrease the risk of hypoglycemia compared to sulphonylurea (SU), is weight neutral, and no dose modification is required over a broad range of patient populations. This consensus paper discusses the clinical efficacy of DPP-4 inhibitors and linagliptin in T2DM. It also highlights the evidence for the safety of linagliptin in T2DM patients with renal impairment (RI), cardiovascular (CV) risk, and heart failure (HF).
Conclusion: Linagliptin therapy is simplifying the management of T2DM with good efficacy and its use across a wide range of patients without any dose modification.
(© Journal of the Association of Physicians of India 2011.)